In Medicaid Waiver, a Challenge to Connect, Collaborate and Create
New York's safety net providers have a new impetus and incentive to collaborate on redesigning how they serve Medicaid patients - if they can make all the moving pieces work.
Single-Payer Advocates Hit Capitol With New Sense Of Reality
Advocates for a single-payer Medicare for all health system are fanning out across Capitol Hill this week, lobbying members of Congress.
Blocking Autophagy With Anti-Malarial Drug Finds Clinical Success
Trials conducted at the Abramson Cancer Center among others have identified the potential of an antimalarial agent, hydroxychloroquine, in stabilizing aggressive cancers.
More Hospice Care Meant Longer Survival, Lower End-of-Life Costs for Metastatic Melanoma Patients
A study in The American Journal of Managed Care found that longer stays in hospice were associated with longer survival and lower end-of-life costs for patients with metastatic melanoma, a particularly deadly and increasingly common form of cancer.
Roche's Gazyvaro Receives Backing of EU's CHMP for CLL
EU's Committee for Medicinal Products for Human Use (CHMP)supported the use of Gazyvaro based on the phase III CLL11 study, wherein treatment with Gazyvaro (obinutuzumab) plus chlorambucil significantly reduced the risk of disease worsening or death by 86% and increased survival time for previously untreated CLL patients compared to those who received treatment with chlorambucil alone.
3 Pathways to Patient-Centered Care
A new report highlights the ways hospitals can identify and address sources of "avoidable suffering" and ultimately improve the patient experience.
EHR Adoption Increases 133% at Community Health Centers
Federally qualified health centers (FQHCs) have increased their EHR adoption by 133% over the past four years, says a report from The Commonwealth Fund, with 93% of FQHCs in possession of an EHR and 85% of these community provider organizations reporting advanced HIT capabilities.
Medical Homes, ACOs Offer Better Business Models
The patient-centered medical home model in Arkansas, which has more than 600 participating providers, helps the state's Medicaid program incentivize quality care instead of paying for volume of services.
A Novel Target for Treating HER2-Positive Breast Cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.
c-Met Signals to Intracellular Rac to Promote Breast Cancer Metastasis
A research article published in Nature Communications identifies a new mechanism of breast cancer metastasis.
Encouraging Results With Vaccine Against Pancreatic Cancer Developed at CINJ
'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.
Repeal of Employer Mandate Could Shake Up Group Insurance
Amid strong lobbying by business groups, support is growing to end the Affordable Care Act's employer mandate, a change that would see millions more Americans buying their health insurance through exchanges.
Lung Cancer Screening could Cost Medicare Billions
A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.
Cigna Plows Ahead with Quality-Based Reimbursement Venture
As part of a contract extension with Tenet Healthcare, Cigna has established a first of its kind quality-based reimbursement agreement.
Cost Prevents Approval of Revlimid in the UK...Again
NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.
Clovis Oncology's Treatment for EGFR-mutant (T790M) NSCLC Patients Receives Breakthrough Designation
CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.
Myriad's Prolaris Diagnostic Kit Holds Value in Prostate Cancer Prognosis
Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.
Geneticists on Both Coasts Issue 'Call to Action' On Need to Share DNA Data
In the new issue of Evidence-Based Oncology, Ellen T. Matloff, MS, CGC, and Rachel E. Barnett, MS, CGC, of the Yale Cancer Center and Robert Nussbaum, MD, of UC San Francisco write that efforts by some genetic testing laboratories to grab market share in the lucrative BRCA testing market may put patients at risk, while violating ethical standards issued by the American Medical Association.
2013 Volume 19 Number SP11
Bundled Payments Could Cut Medicare Fraud, Experts Say
Health and policy experts are pushing for a system that pays doctors a lump sum for medical care or allows them to share in savings, saying it will save millions of dollars over current fee-for-service payments that can lead to fraud and over-use of medications.
Higher Health Insurance Cost-Sharing Impacts Asthma Care for Low-Iincome Kids
Parents in low-income families were less likely to delay asthma care for their children or avoid taking their children to see a doctor is they had lower vs. higher levels of health insurance cost-sharing.
Encouraging Results With Radioimmunotherapy and Gemcitabine Treatment in Metastatic PDAC
Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.
Arzerra Fails in Phase 3 Trial for B-cell Lymphoma
GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.
States Stick to Insurance Exchange Models
Few states could claim Obamacare's first enrollment period was smooth-whatever the final numbers-but most will approach their insurance exchanges the same way for the 2015 window. None has asked the Obama administration to take over its marketplace or elected to abandon in favor of running its own.
Takeda Unveils Phase 3 ELM-PC4 Trial Data in Men With Chemotherapy-Naive mCRPC
Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.